Laddar...
Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib
Approximately 40% of chronic myeloid leukemia (CML) patients who discontinue imatinib (IM) therapy maintain undetectable minimal residual disease (UMRD) for more than one year (stopping IM (STOP-IM)). To determine a possible biomarker for STOP-IM CML, we examined plasma miRNA expression in CML patie...
Sparad:
I publikationen: | Int J Mol Sci |
---|---|
Huvudupphovsmän: | , , , , , , , , |
Materialtyp: | Artigo |
Språk: | Inglês |
Publicerad: |
MDPI
2016
|
Ämnen: | |
Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4849026/ https://ncbi.nlm.nih.gov/pubmed/27092489 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms17040570 |
Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|